Reporter brief
RCT of anti-inflammatory agents for choroidal neovascularization in age-related macular degeneration
What happened
This randomised controlled trial evaluated whether infliximab, sirolimus, or daclizumab combined with standard AMD care would prevent new blood vessel growth in the eye compared to observation alone. The study enrolled participants aged 55+ with AMD and drusen >63 μm, with baseline vision between 20/20 and 20/400. Participants received one of three treatments or observation only, with evaluations at 6 months including retinal imaging, angiography, and blood tests.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Participants 55 years of age and older with age-related macular degeneration (AMD) and drusen larger than 63 μm. Vision in the study eye was between 20/20 and 20/400.
- Design
- Rct
- Sample
- —
- Journal
- National Eye Institute (NEI)
- Published
- Nov 29, 2016
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.